HIV Infections
Conditions
Keywords
Drug Therapy, Combination, HIV Protease Inhibitors, Ritonavir, VX 478, Salvage Therapy, Anti-HIV Agents, Drug Monitoring, Nelfinavir, Treatment Experienced
Brief summary
The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.
Detailed description
HIV-infected patients will be treated with a ritonavir-enhanced Agenerase regimen.
Interventions
DRUGRitonavir
DRUGAmprenavir
Sponsors
Gathe, Joseph, M.D.
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients may be eligible for this study if they: * Are 18 years of age or older. * Are HIV-positive. * Have a viral load (level of HIV in the body) of more than 1,000 copies/ml. * Have had more than 12 weeks of prior anti-HIV drug treatment. * Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor. * Are responsive to Agenerase. * Are able to follow study requirements.
Exclusion criteria
Patients will not be eligible for this study if they: * Are intolerant to ritonavir (an anti-HIV drug). * Have or have had problems with absorption. * Have liver disease or damage. * Have pancreatic disease or damage. * Have taken any protease inhibitor other than nelfinavir. * Are receiving investigational drugs or devices from another study. * Are pregnant or breast-feeding. * Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide. * Have a bleeding disorder. * Have previously been treated with Agenerase. * Are receiving nonnucleosides.
Countries
United States
Outcome results
None listed